SARS News and Research

RSS

Researchers use nanotechnology to develop new coronavirus mask model

A US-based research team designed and fabricated electrospun nanofibrous air filters that hold promise for applications in personal protective equipment and indoor environments. The team compared the filtration efficiency of coronavirus and NaCl aerosols to a broad spectrum of electrospun air filters and face masks.

7 Jan 2021

Scientists to help nursing homes implement best practices to mitigate COVID-19 impact

Researchers in Georgia State University's School of Public Health and Emory University's School of Medicine have received a $600,000 grant from the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality to help nursing homes implement practices to mitigate the impact of COVID-19 and stop the spread of the SARS-CoV-2 virus.

7 Jan 2021

Danish study suggests local lockdown had no effect on SARS-CoV-2 infection rate

The onset of the coronavirus disease 2019 (COVID-19) pandemic led to severe restrictions on public mobility and interaction, national or state-wide lockdowns, school and workplace closures, and curfews. The result was widespread economic hardship, in addition to the toll on health.

7 Jan 2021

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Researchers who studied antibody and immune cell responses in more than 180 men and women who had recovered from COVID-19 report these patients' immune memory to the virus - across all immune cell types studied - was measurable for up to 8 months after symptoms appeared.

7 Jan 2021

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thought to have a zoonotic origin, perhaps originating in a bat coronavirus with an unknown intermediate host. It is not only very infectious but has been found to infect a wide range of mammals, including dogs, cats, ferrets, hamsters, and minks, besides non-human primates. This range may be still higher, claims a recent preprint that appeared in January 2021 on the bioRxiv server.

6 Jan 2021

Adaptive immune system against COVID-19 can last for at least eight months

New data suggest that nearly all COVID-19 survivors have the immune cells necessary to fight re-infection.

6 Jan 2021

Is one-dose COVID-19 vaccination better than two?

A recent study published on the preprint server medRxiv in December 2020 reflects on the possibility of using a single-dose vaccine regimen to accomplish large-scale vaccination as early as possible.

6 Jan 2021

Increased socializing may have jeopardized lockdown benefit in England

Researchers in the UK report that much of the potential beneficial impact of the November 2020 English National lockdown on the coronavirus disease 2019 (COVID-19) epidemic was likely undermined in many areas due to increased socializing in the days running up to its implementation.

6 Jan 2021

More stringent measures may be needed to control new SARS-CoV-2 B.1.1.7 variant in England

Researchers in the UK have conducted a comprehensive epidemiologic analysis of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in an effort to learn more about the expanded range and frequency of coronavirus disease 2019 (COVID-19) cases in England.

6 Jan 2021

In-silico modeling provides new understanding of immune response to SARS-CoV-2

The COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has crippled global healthcare systems and triggered an economic crisis in many countries. The pandemic is not showing signs of a slowdown even in 2021 with a new and more infectious variant of the virus wreaking havoc in the UK and many other parts of the world.

6 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

In a recent bioRxiv* preprint paper, US researchers mapped in detail how mutations to the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affected antibody binding in convalescent human serum – and revealed that it is influenced by mutations at only a handful of dominant epitopes.

6 Jan 2021

Smokers at increased risk of developing symptomatic COVID-19

Smoking is associated with an increased risk of COVID-19 symptoms and smokers are more likely to attend hospital than non-smokers, a study has found.

6 Jan 2021

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

A large clinical trial, known as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2), is set to take place, which aims to test monoclonal antibody efficacy and safety in people who have mild or moderate COVID-19.

6 Jan 2021

Vitamin D supplementation found to reduce COVID-19-related mortality, says study

Researchers have shown that prescribing vitamin D supplementation to COVID-19 patients seems to decrease the mortality rate, the severity of the disease, and serum levels of inflammatory markers.

6 Jan 2021

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Researchers recently demonstrated that chemical agents capable of reducing disulfide (S-S) bonds can be potentially used as antiviral drugs against SARS-CoV-2, the causative pathogen of COVID-19.

6 Jan 2021

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

A new study shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.

6 Jan 2021

Are SARS-CoV-2 antibodies associated with disease enhancement?

As SARS-CoV-2 continues to wreak its havoc, antibodies that neutralize the virus and protect against infection have become an important focus of research. However, there is a concern as to whether these antibodies can actually enhance the disease.

6 Jan 2021

Researchers claim SARS-CoV-2 B.1.1.7 variant likely to become globally dominant

The new variant of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) detected in England replicates more than two times faster than the earlier strains. This replication advantage promises to make it the dominant global variant very shortly. This finding comes from a startling preprint that appeared on the medRxiv* server in December 2020.

6 Jan 2021

New mathematical model proposes optimal treatment strategies for COVID-19

Getting control of COVID-19 will take more than widespread vaccination; it will also require a better understanding of why the disease causes no apparent symptoms in some people but leads to rapid multi-organ failure and death in others, as well as better insight into what treatments work best and for which patients.

5 Jan 2021

SARS News and Research

Researchers use nanotechnology to develop new coronavirus mask model

Scientists to help nursing homes implement best practices to mitigate COVID-19 impact

Danish study suggests local lockdown had no effect on SARS-CoV-2 infection rate

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

Adaptive immune system against COVID-19 can last for at least eight months

Is one-dose COVID-19 vaccination better than two?

Increased socializing may have jeopardized lockdown benefit in England

More stringent measures may be needed to control new SARS-CoV-2 B.1.1.7 variant in England

In-silico modeling provides new understanding of immune response to SARS-CoV-2

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

Smokers at increased risk of developing symptomatic COVID-19

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

Vitamin D supplementation found to reduce COVID-19-related mortality, says study

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

Are SARS-CoV-2 antibodies associated with disease enhancement?

Researchers claim SARS-CoV-2 B.1.1.7 variant likely to become globally dominant

New mathematical model proposes optimal treatment strategies for COVID-19

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News